Balanced news tone
News Sentiment
LUNG sentiment intelligence
Pulmonx Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
49
Balanced news tone
57 relevant articles
Price is moving more forcefully than the current news tone suggests.
77/100 classification confidence.
directly relevant articles
high-authority source matches
+10.8% over one week, +12.4% over four weeks, trend inactive, and below fair value.
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Earnings
77/100 classification
One-week reaction
10.8%
Price confirming higher
Trend fit
Trend inactive
12.4% over four weeks
Fair value
-74.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
42
Negative
10
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
marketscreener.com
Direct company coverage
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 20:05
- Source
- marketscreener.com
Stock Titan
Direct company coverage
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results
Pulmonx (Nasdaq: LUNG) announced it will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via their
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 19:41
- Source
- Stock Titan
Market source
Industry context
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
MarketBeat
Direct company coverage
Yun-Lung Chen Sells 5,958 Shares of Ambarella (NASDAQ:AMBA) Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:09
- Source
- MarketBeat
Kalkine Media
Direct company coverage
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz
Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This r
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 09 Jul 2026 20:45
- Source
- Kalkine Media
AD HOC NEWS
Direct company coverage
Pulmonx Corp highlights lung device strategy as a specialized medtech player
Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associ
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Jul 2026 19:32
- Source
- AD HOC NEWS
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF
This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 06:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Pulmonx Corp. – LSX:A2P1AF
This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data avai
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 04:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Pulmonx Corp. – LSX:A2P1AF
This article provides the "Price to earnings forward" valuation metric for Pulmonx Corp. (LSX:A2P1AF). It indicates the value and change of this financial data point over a period. The information is presented within the context of TradingView's platform, which offers various fin
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 02:10
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Pulmonx Corp. – DUS:4NI
This article provides the "Price to earnings forward" data for Pulmonx Corp. (DUS:4NI) on the TradingView platform. It details the company's financial information, presented within the context of the Düsseldorf Stock Exchange. The content is primarily a data page on a financial p
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 01:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Pulmonx Corp. – DUS:4NI
This page from TradingView provides financial information for Pulmonx Corp. (4NI) listed on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-sales ratio. The article includes standard market data and copyright information, indicating that the market fo
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jul 2026 01:10
- Source
- TradingView
Ad-hoc-news.de
Direct company coverage
Pulmonx Corp highlights its respiratory device portfolio as investors assess long-term growth prospects
Pulmonx Corp (PULM) focuses on developing minimally invasive medical devices for severe emphysema and other chronic obstructive pulmonary diseases, targeting a significant unmet medical need. The company's business model involves selling specialized devices to healthcare provider
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 15:40
- Source
- Ad-hoc-news.de
TradingView
Direct company coverage
Pulmonx Corp. Actuals & Estimates (NASDAQ:LUNG)
This article provides financial actuals and estimates for Pulmonx Corporation (NASDAQ: LUNG), including its current stock price, historical performance, analyst forecasts, and company financials. It details the company's market capitalization, last quarter's earnings and revenue,
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 26 Jun 2026 01:11
- Source
- TradingView
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis
Pulmonx Corp (LUNG) has a stable financial status but low operating efficiency, ranking 142 out of 204 in the Healthcare Equipment & Supplies industry with a financial score of 6.69. The company's latest quarterly revenue decreased by 8.66% year-over-year to $20.59 million, and i
- Tone
- Negative 40/100
- Event
- Earnings
- Published
- 23 Jun 2026 23:40
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pulmonx Corp (LUNG), highlighting its price momentum score of 5.32 within the Healthcare Equipment & Supplies industry. It details the stock's current trading range between a resistance level of $1.59 and a support level of $1.09, sug
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 18 Jun 2026 22:09
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Pulmonx Corp (LUNG), highlighting its current earnings forecast score, average price target of $4.50, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend. The article also includes expected revenue and EPS for upcom
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 18 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Institutional Confidence
Pulmonx Corp (LUNG) has an institutional shareholding score of 7.00, placing it 79th out of 204 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 10.02% quarter-over-quarter to 87.40%. James Simons is noted as the largest inst
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 18 Jun 2026 11:09
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Pulmonx Corp (LUNG), noting its current valuation score is 7.71, ranking 137 out of 204 in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio of -0.97, which represents a decrease from its recent high
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 10:09
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pulmonx Corp's (LUNG) dividend and stock split history, noting that no dividend data or stock split data is available. It shows the current stock price, market cap, and links to various company and market analysis sections on the TradingKey pl
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 21:09
- Source
- TradingKey
TradingKey
Direct company coverage
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulmonx Corp (LUNG), detailing its revenue by geographical region for the fiscal year 2023. The United States contributed the largest portion of revenue at 63.01% ($57.02 million), followed by Europe, Middle-East and Africa ("EMEA") a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 21:09
- Source
- TradingKey
Market source
Industry context
Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
[Form 4] Pulmonx Corp Insider Trading Activity
Pulmonx Corp director Thomas William Burns has been granted 40,000 Restricted Stock Units (RSUs) as compensation, not through a market purchase. These RSUs, valued at $0.0000 per share, will vest on the earlier of one year from the June 5, 2026 grant date or the date of the Annua
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 18:39
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pulmonx (LUNG) director receives 40,000-share RSU stock grant
Pulmonx Corp director Dana G. Mead Jr. was granted 40,000 Restricted Stock Units (RSUs) which are payable in common stock. This is an equity compensation award, not an open-market purchase, with a grant price of $0.00 per share. These RSUs will vest on the earlier of June 5, 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 06:40
- Source
- Stock Titan
Stock Titan
Direct company coverage
LUNG SEC Filings - Pulmonx Corp 10-K, 10-Q, 8-K Forms
This page provides access to SEC filings for Pulmonx Corporation (LUNG), a medical technology company. It includes 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. The filings detail the company's financial results, governance, compensa
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jun 2026 03:39
- Source
- Stock Titan
Sahm
Direct company coverage
Don't Ignore The Insider Selling In Pulmonx
Pulmonx Corporation's CEO and President, Glendon French, recently sold US$87k worth of stock at US$1.55 per share, following an earlier sale of US$97k below the current price. Insiders own 5.1% of Pulmonx shares, worth approximately US$3.3m, but there have been no insider purchas
- Tone
- Negative 29/100
- Event
- Market update
- Published
- 07 Jun 2026 22:11
- Source
- Sahm
Stock Titan
Direct company coverage
Pulmonx (LUNG) officer sells 14,497 shares to cover RSU tax withholding
Pulmonx Corp's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,497 shares of common stock on June 1, 2026, across four transactions at $1.54 per share. These sales totaling $22,325 were made exclusively to cover tax withholding obligations stemming from the ve
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 16:09
- Source
- Stock Titan
Investing.com UK
Direct company coverage
Pulmonx general counsel David Lehman sells $22,474 in stock
David Aaron Lehman, General Counsel at Pulmonx Corp, sold 14,594 shares of company stock worth $22,474 on June 1, 2026, to cover tax obligations from vested RSUs. This transaction occurred as Pulmonx faces financial challenges, including quickly burning through cash and remaining
- Tone
- Negative 30/100
- Event
- Balance sheet
- Published
- 04 Jun 2026 04:40
- Source
- Investing.com UK
Stock Titan
Direct company coverage
Pulmonx (LUNG) CCO sells shares to cover RSU tax obligations
Pulmonx Corp's Chief Commercial Officer, Geoffrey Beran Rose, sold 8,023 shares of common stock at $1.54 per share on June 1, 2026. These sales were conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units from 2023, 2024, 2025, and
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pulmonx (LUNG) General Counsel sells 14,594 shares to cover RSU tax obligations
Pulmonx Corp General Counsel David Aaron Lehman sold 14,594 shares of common stock at $1.54 per share on June 1, 2026. These sales were executed in four transactions solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 202
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 20:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Pulmonx (LUNG) CEO logs 56K-share sale tied to RSU tax withholding
Pulmonx Corp CEO Glendon E. French III sold 56,149 shares of common stock on June 1-2, 2026, at prices between $1.54 and $1.57 per share. These sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted on March 1, 2023, a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 20:09
- Source
- Stock Titan